• Explore /
  • Poster
  • / Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.

Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.

Abstract Poster

Authors

null

Scott N. Gettinger

Yale Cancer Center, New Haven, CT

Scott N. Gettinger , Frederick Hugh Wilson , Sarah B. Goldberg , Anne C. Chiang , Brian S. Henick , Elin Rowen , Heather Gerrish , Emily Duffield , Marianne Davies , Vanna Dest , Annette Komlo , Jennifer Pope , Wei Cheng , Kurt A. Schalper , Roy S. Herbst

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03262779

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9121)

DOI

10.1200/JCO.2023.41.16_suppl.9121

Abstract #

9121

Poster Bd #

109

Abstract Disclosures

Similar Posters

First Author: Luis G. Paz-Ares

Poster

2020 ASCO Virtual Scientific Program

A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).

A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).

First Author: Alona Zer

First Author: Meredith M. Regan

First Author: Kohei Shitara